OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business

OpenAI has acquired biotech startup Orchestra Bio, marking a move to strengthen its business in the biotechnology sector.

A step into biotechnology

The acquisition brings Orchestra Bio into OpenAI as the company looks to build up its biotech operations. The available information does not include financial terms or additional details about the transaction.

What is known about the deal

Orchestra Bio is identified as a startup, while the acquisition positions the company within OpenAI’s broader biotechnology efforts. No further information has been provided about the startup’s technology, team or future role.

The deal underscores OpenAI’s interest in expanding beyond its core artificial intelligence business, although the scope and potential impact of the acquisition remain unspecified.